LENTIVIRUS MODEL FOR AIDS CHEMOTHERAPY

艾滋病化疗的慢病毒模型

• 批准号: 2064287
• 负责人: RICHARD J. BRIDGES
• 金额: $ 27.71万
• 依托单位: UNIVERSITY OF MONTANA
• 依托单位国家: 美国
• 财政年份: 1988
• 资助国家: 美国
• 起止时间: 1988-09-30 至 1995-06-09
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2064287
• 关键词: AIDS; AIDS therapy; RNA directed DNA polymerase; Retroviridae; Retroviridae disease; cats; disease /disorder model; drug resistance; drug screening /evaluation; genetic mapping; human immunodeficiency virus 1; model design /development

DESCRIPTION: (Adapted from applicant's abstract) The long range goal of this project is to develop a model system for evaluation of anti-retroviral drugs and to use this system in the design and evaluation of therapeutic agents for treatment of human acquired immune deficiency syndrome (AIDS). The model which has been developed is feline immunodeficiency virus (FIV), a lentivirus associated with immunodeficiency in cats which is very similar to AIDS in humans. The specific aims of the project are to isolate and characterize sets of azidothymidine (AZT)-resistant mutants of FIV. Attempts will also be made to isolate FIV mutants resistant to other reverse transcriptase (RT)-targeted antivirals. Analysis of these mutants will be facilitated by a focal infectivity assay for FIV developed by this laboratory. The cross-resistance of each mutant to other antivirals will be determined and experiments will be carried out to determine whether the mutants revert. Mutations in the pol (specifies viral reverse transcriptase) gene will be mapped by sequence analysis and the RT of selected mutants will be characterized. Attempts will also be made to select mutants of FIV with multiple drug resistance. The pathogenicity of selected mutants will be evaluated in specific pathogen free cats.

描述：（改编自申请人的摘要）的长期目标